Physician profile
Julie Bascones
NPI 1740773183
$1,679.59
in general payments reported to CMS, 2019-2025
27 companies · $684 in 2025
The $684 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.86 · 2022: $78.14 · 2023: $151 · 2024: $727 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $356.09 | 2024-2025 | |
| Pfizer INC. | $225.15 | 2022-2024 | |
| Kedrion Biopharma, INC. | $147.97 | 2024-2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Merck Sharp & Dohme LLC | $116.35 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $73.42 | 2025 | Vonvendi, Advate |
| Novo Nordisk INC | $70.96 | 2024-2025 | Alhemo |
| Acadia Pharmaceuticals INC | $54.39 | 2024 | Daybue |
| Cranial Technologies, INC | $48.63 | 2022-2024 | Doc Band |
| Octapharma USA, INC. | $46.38 | 2024-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Jazz Pharmaceuticals INC. | $43.48 | 2024 | |
| Glaxosmithkline, LLC. | $41.97 | 2021-2023 | Bexsero |
| Incyte Corporation | $41.43 | 2025 | Jakafi, Niktimvo |
| Pharmacosmos Therapeutics INC. | $34.86 | 2024 | Monoferric |
| Chiesi USA, INC. | $34.70 | 2025 | Elfabrio |
| Biomarin Pharmaceutical INC. | $34.64 | 2024 | Roctavian |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $30.88 | 2024 | Danyelza |
| Sobi, INC | $28.96 | 2024 | |
| Biogen, INC. | $28.22 | 2025 | Spinraza |
| Novartis Pharmaceuticals Corporation | $27.55 | 2025 | |
| Pharming Healthcare, INC. | $27.53 | 2024 | Ruconest |
| Seqirus USA INC | $27.43 | 2023 | Flucelvax Quadrivalent |
| Boston Scientific Corporation | $27.05 | 2021 | |
| Kyowa Kirin, INC. | $26.90 | 2024 | Crysvita |
| Springworks Therapeutics, INC. | $25.78 | 2025 | Gomekli |
| Genentech USA, INC. | $23.83 | 2024 | Hemlibra |
| Intrabio INC | $19.73 | 2025 | Aqneursa |
| Sanofi Pasteur INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bascones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.